Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- AZ Jan Palfijn Gent
- Target Recruit Count
- 120
- Registration Number
- NCT01682642
- Locations
- 🇧🇪
AZ Jan Palfijn, Gent, Oost-vlaanderen, Belgium
Tecemotide (L-BLP25) in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 28
- Registration Number
- NCT01496131
- Locations
- 🇺🇸
Please Contact US Medical Information, Rockland, Massachusetts, United States
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01377389
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 147
- Registration Number
- NCT01266213
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 203
- Registration Number
- NCT01252693
- Locations
- 🇺🇸
Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸The Urology Center of Colorado, Denver, Colorado, United States
🇺🇸Urology San Antonio Research, San Antonio, Texas, United States
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT01250717
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240941
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240928
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01205685
- Locations
- 🇺🇸
Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States
Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01013506
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.